Abstract:Background: Altered small intestinal motility in cirrhotics may play a major role in the development of bacterial translocation (BT) by leading to small intestinal bacterial overgrowth. BT has been implicated in the development of several complications including spontaneous bacterial peritonitis, esophageal variceal hemorrhage, and hepatorenal syndrome. Prior studies using antroduodenal manometry to evaluate intestinal motility have shown discrepancies regarding the relationship between dysmotility and the severity of cirrhosis. Objectives: (1) To characterize the frequency of small bowel motility disturbances in cirrhotic patients using a wireless motility capsule (SmartPill); (2) To assess the relationship of intestinal dysmotility with liver disease severity and cirrhosis complications; and (3) To compare intestinal transit times and motility indices among cirrhotics and healthy controls. Methods: We conducted a prospective study of 20 patients with cirrhosis (10 compensated, 10 decompensated) who were recruited from Yale New Haven Hospital and Hepatology clinics (February 2011 to July 2011). All patients underwent and completed SmartPill studies. Intestinal transit times were calculated, analyzed, and compared among compensated versus decompensated cirrhotics versus historical, healthy controls. Intestinal transit delays/motility indices were correlated with disease severity and complications. Results: Decompensated cirrhotics had significantly longer small bowel transit times (SBTT) as compared with compensated cirrhotics (6.17 vs. 3.56 h, P=0.036). There was a significant correlation (r=0.77, P=0.0003) between SBTT and cirrhosis severity as assessed by Child-Pugh score. There were no statistical differences noted between the groups for gastric or colonic transit times, although there was a trend toward prolonged transit throughout the gut in decompensated. Cirrhotics with spontaneous bacterial peritonitis and ascites also had significantly longer SBTT as compared with those without. Conclusions: This study demonstrates that decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls. Additional prospective studies are needed to further characterize dysmotility in cirrhotics and its relationship to complications related to BT. This would aid in the identification of patients at risk for developing severe complications and who may benefit from prophylactic prokinetic and/or antimicrobial therapy.

Small Bowel Transit and Altered Gut Microbiota in Patients with Liver Cirrhosis

Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis.

Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations with Gastrointestinal Symptoms

Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection

Intestinal Microbiota and Innate Immunity-Related Gene Alteration in Cirrhotic Rats with Liver Transplantation

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients.

Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China

Alterations of the human gut microbiome in liver cirrhosis

Characteristics of Three Microbial Colonization States in the Duodenum of the Cirrhotic Patients.

Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.

IDDF2024-ABS-0186 Analysis of the Correlation Between Gut Microbiota and Disease Severity in Patients with Primary Biliary Cholangitis

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

Alterations in the intestinal microbiome and metabolic profile of patients with cirrhosis supplemented with lactulose, Clostridium butyricum, and Bifidobacterium longum infantis: a randomized placebo-controlled trial

Exploring the diagnostic potential of immunoglobulin A-microbiota interplay in liver cirrhosis and spontaneous bacterial peritonitis

Comparison of the Gut Microbe Profiles and Numbers Between Patients with Liver Cirrhosis and Healthy Individuals

Gut microbiota of patients with cirrhosis promotes cirrhosis development by injuring intestinal mucosal barrier in mice

Alterations in Intestinal Microbiota Relate to Intestinal Failure-Associated Liver Disease and Central Line Infections.

Mucosa-Associated Microbial Profile Is Altered in Small Intestinal Bacterial Overgrowth

Decompensated Cirrhotics Have Slower Intestinal Transit Times As Compared with Compensated Cirrhotics and Healthy Controls